TNFA
TNF Pharmaceuticals, Inc. Common Stock
stock NASDAQ

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.